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OBJECTIVES We sought to elucidate how the local activation of matrix metalloproteinases (MMPs) is
balanced by that of the endogenous tissue inhibitors of MMP (TIMPs) during left ventricular
(LV) remodeling.
BACKGROUND Although it is known that the extracellular matrix (ECM) must be altered during LV
remodeling, its local regulation has not been fully elucidated.
METHODS In Dahl salt-sensitive rats with hypertension, in which a stage of concentric, compensated left
ventricular hypertrophy (LVH) at 11 weeks is followed by a distinct stage of congestive heart
failure (CHF) with LV enlargement and dysfunction at 17 weeks, we determined protein and
messenger ribonucleic acid (mRNA) levels of LV myocardial TIMP-2 and -4 and MMP-2,
as well as their concomitant activities.
RESULTS No changes were found at the LVH stage. However, during the transition to CHF, TIMP-2
and -4 activities, protein and mRNA levels were all sharply increased. At the same time, the
MMP-2 mRNA and protein levels and activities, as determined by gelatin zymography, as
well as by an antibody capture assay, showed a substantial increase during the transition to
CHF. The net MMP activities were closely related to increases in LV diameter (r  0.763)
and to systolic wall stress (r  0.858) in vivo.
CONCLUSIONS Both TIMPs and MMP-2 remained inactive during hypertrophy, per se; they were activated
during the transition to CHF. At this time, the activation of MMP-2 surpassed
that of TIMPs, possibly resulting in ECM breakdown and progression of LV
enlargement. (J Am Coll Cardiol 2002;39:1384–91) © 2002 by the American College of
Cardiology Foundation
Left ventricular hypertrophy (LVH) is an adaptive response
to various mechanical and hormonal stimuli, but eventually
it causes congestive heart failure (CHF) (1). Among several
pathologic factors that might be activated during the tran-
sition from adaptive LVH to CHF, qualitative and quanti-
tative changes of the myocardial extracellular matrix (ECM)
may be the critical ones inducing changes in myocyte
alignment and, thus, remodeling of the left ventricular (LV)
geometry (2–5). However, the cellular and molecular mech-
anisms regulating myocardial ECM remain poorly under-
stood.
Matrix metalloproteinases (MMPs) belong to a family of
proteolytic enzymes that has been implicated as playing a
key role in ECM degradation in several disorders (6).
Experimental animal hearts (7,8) and human hearts (9) with
advanced heart failure have also shown increases in MMP
enzyme activity or messenger ribonucleic acid (mRNA)
levels. However, the actual proteolysis that occurs might
depend on a balance between MMPs and the tissue inhib-
itors of MMP (TIMPs) (10). Also, the net activity of
MMPs and its correlation with the process of chamber
remodeling have not yet been clarified. Thus, in the present
study, using an animal model in which the process from
mechanically compensated LV hypertrophy to heart failure
can be clearly distinguished, we examined whether an
imbalance between MMPs and TIMPs may occur concur-
rently with the progression of hypertrophy or with the
transition to heart failure (11).
METHODS
Experimental animals and in vivo assessment of LV
geometry and function. Male inbred Dahl salt-sensitive
(DS) rats were fed an 8% sodium chloride (high-salt) diet
after the age of six weeks (11). The animals were sacrificed
at the stages of LVH (11 weeks, n  16) and CHF (17
weeks, n  15). Normotensive Dahl salt-resistant (DR)
rats were used as the age-matched control animals (sacri-
ficed at 11 weeks [LVH stage, n  14] and 17 weeks
[CHF stage, n  14]). Systolic blood pressure and the
echocardiographically guided LV dimension were measured
(11) on the day before sacrifice. The animals were treated
in accordance with the “Position of the American Heart
Association on Research Animal Use,” adopted by the
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Northern and Western blot analyses. Total ribonucleic
acid was isolated from the LV by using the acid guani-
dinium thiocyanate-phenol-chloroform method. The com-
plementary deoxyribonucleic acid (cDNA) probes used in
this study were the following: 1) TIMP-2, a 378-base pair
(bp) fragment isolated by reverse transcriptase-polymerase
chain reaction (RT-PCR) amplification, with primers com-
plementary to positions 513 to 890 of the rat cDNA
sequence (12); 2) TIMP-4, a 375-bp fragment isolated by
RT-PCR amplification, with primers complementary to
positions 111 to 485 of the rat cDNA sequence (13); 3)
MMP-2, a 301-bp fragment isolated by RT-PCR, with
primers complementary to positions 1666 to 1966 of the rat
cDNA sequence (14); and 4) human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), purchased from the
American Type Culture Collection (Manassas, Virginia).
The polymerase chain reaction products were purified and
subcloned into pBluescript (Stratagene, La Jolla, Califor-
nia). The results of Northern blotting of each sample were
normalized by the amount of GAPDH mRNA.
Forty micrograms of homogenized LV protein was elec-
trophoresed under reducing conditions on 8% polyacryl-
amide gels and transferred to nitrocellulose filters (Hybond
ECL, Amersham, Buckinghamshire, United Kingdom).
Membranes were incubated with specific rabbit anti–
TIMP-2, TIMP-4 and MMP-2 antibodies (Chemicon
International, Temecula, California) as the primary anti-
bodies, at a dilution of 1:3,000, and with horseradish
peroxidase-conjugated goat anti-rabbit antibody as the sec-
ondary antibody, at a dilution of 1:2,000. The immune
complexes were detected with a chemiluminescence kit
(ECL, Amersham).
Quantitative zymography and reverse zymography. The
zymographic method for the measurement of MMPs
in the rat myocardium has been described previously
(15). Gelatin (Sigma Chemical Co., St. Louis, Missouri)
was used as a substrate and was added to a standard 8%
polyacrylamide gel mix to achieve a final concentration of
1 mg/ml. Samples (40 g) and 0.2 to 1.0 g of purified
human MMP-2 (Chemicon) were directly loaded onto gels
under nonreducing conditions. After electrophoresis, the
gels were twice soaked in 2.5% Triton X-100 (Sigma) for
30 min at room temperature, rinsed in water and incubated
overnight (12 h) at 37°C in substrate buffer (50 mmol/l
Tris-HCl [pH 8], 5 mmol/l CaCl2 and 0.02% NaN3). After
incubation, the gels were stained for 30 min in 0.125%
Coomassie blue R-250 and then destained in 30% ethanol
and 10% acetic acid in water.
Quantitative reverse zymography was performed as re-
cently described (16). Protein extracts were subjected to
12% polyacrylamide gels containing 2.25% gelatin and
latent 72-kDa gelatinase (Biogenesis, Poole, England).
After incubation overnight at 37°C, the gels were stained
with Coomassie blue R-250. Activity of TIMP appeared as
a dark band where MMP-related gelatinase activity was
blocked.
Measurement of active MMP-2 levels by antibody cap-
ture assay. The endogenous levels of active MMP-2 were
measured without p-aminophenylmercuric acetate by using
an antibody capture method, according to the manufactur-
er’s instructions (RPN2631, Amersham Pharmacia Biotech)
(17).
Statistical analysis. All data are expressed as the mean
value  SEM. The significance of differences among the
mean values of two factors—age (LVH at 11 weeks and
CHF at 17 weeks) and type (DS and DR)—was analyzed by
two-way factorial analysis of variance. We have also de-
scribed three p values: pa for the age factor; pt for the type
factor; and pi for the interaction. When there was an
interaction between two factors, various groups were ana-
lyzed with post-hoc comparisons by using the Tukey-
Kramer test. The other groups were analyzed with the t test
for each factor. In all tests, p  0.05 was considered
statistically significant.
RESULTS
Heart weight, systolic blood pressure and echocardiog-
raphy at the LVH and CHF stages. The systolic blood
pressure, LV weight and echocardiographic measurements
are presented in Table 1. At 11 weeks, the DS rats showed
concentric LVH, as reported previously (11). Systolic LV
wall stress was equal for these two groups, implying that
mechanical compensation had been established for the
increased afterload. At 17 weeks, the LV diameter increased
by 18% in the DS rats, and this was associated with a 56%
decrease in fractional shortening and a 3.4-fold increase in
LV wall stress. Thus, along with the process of mechanical
decompensation against excessive afterload, the LV geom-
etry showed an alteration from the concentric to the
eccentric pattern of hypertrophy (i.e., LV remodeling).
Abbreviations and Acronyms
bp  base pair
cDNA  complementary deoxyribonucleic acid
CHF  congestive heart failure
DR  Dahl salt-resistant
DS  Dahl salt-sensitive
ECM  extracellular matrix
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
LV  left ventricular
LVH  left ventricular hypertrophy
MMP  matrix metalloproteinase
mRNA  messenger ribonucleic acid
RT-PCR  reverse transcriptase-polymerase chain
reaction
TIMP  tissue inhibitor of matrix metalloproteinase
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Expression of TIMP during the transition from LVH to
CHF. The TIMP activity was quantified as the density of
a 21-kDa single band on the reverse zymogram, which
corresponded to TIMP-2 and TIMP-4 (Fig. 1). The
activity was the same for the DS and DR rats at 11 weeks.
However, it showed an increase of 103% at 17 weeks
(1.81  0.2 in 17-week-old DS rats vs. 0.89  0.1 in
17-week-old DR rats; p  0.01). The levels of TIMP
protein and mRNA were also quantified using the same
method (Fig. 2). In the 17-week-old DS rats, TIMP-2 and
-4 protein levels were increased by 21.7% and 56.8%,
respectively. The TIMP-2 mRNA increased by 112% in the
11-week-old DS rats and by 142% in the 17-week-old DS
rats. The TIMP-4 mRNA levels remained unchanged at 11
weeks; however, it increased by 77% at 17 weeks. Taken
together, the TIMPs were regulated at their transcriptional
level and were not activated by hypertrophy, per se. How-
ever, they were activated during the transition to heart
failure.
Expression of MMP during the transition from LVH to
CHF. The activity of MMP-2 in cardiac extracts was
quantified as a band of gelatinolytic activity, based on its
specific molecular weight (54, 68 and 72 kDa), which was
confirmed by comparison with commercially available, pure
MMP-2 (Fig. 3A) (18), whose proteolytic activity was
inhibited by ethylenediamine-tetraacetic acid but not by
phenylmethyl sulfonyl fluoride (data not shown). Only
MMP-2 activity was detected on the gelatin zymogram.
The net MMP activity was unchanged for both the DS and
DR rats at 11 weeks. In contrast, at 17 weeks, the net MMP
activity in the DS rats showed an 89.2% increase, as
compared with that in the age-matched DR rats (Fig. 3B).
We also calculated the ratio of 68- to 72-kDa bands on the
zymogram (Fig. 3C). The ratio was significantly increased
in rats with CHF as compared with the age-matched DR
rats and DS rats at 11 weeks. The protein level of MMP-2
showed changes that paralleled its gelatinolytic activity
(1.7  0.2 arbitrary unit in the DS rats with CHF vs. 1.0 
0.1 in 17-week-old DR rats; p  0.01) (Fig. 4A). The
MMP-2 mRNA level was also significantly increased at 17
weeks in the DS rats (2.26  0.05, p  0.01), as compared
with that of the DS rats at 11 weeks (1.48  0.15) and the
age-matched DR rats (1.21  0.22, p  0.01) (Fig. 4B).
When the net MMP activity of each animal was plotted
against the in vivo LV variables, the MMP activity showed
a linear correlation with the LV end-diastolic diameter (r 
0.763) and with LV systolic wall stress (r  0.858). Thus,
MMP activation occurred in a manner parallel to that of LV
remodeling.
Endogenous levels of active MMP-2. The endogenous
levels of active MMP-2 were further determined by an
antibody capture assay. The active MMP-2 level of the DS
rats with CHF (2.14 0.04 ng/ml) was significantly higher
than that of the age-matched DR rats (1.81  0.06 ng/ml,
p  0.01) and the DS rats at 11 weeks (1.95  0.04 ng/ml,
p  0.01), by using the t test. The results were consistentTa
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with the MMP-2 activity determined by gelatin zymogra-
phy. In this case, the three p values are pa  0.0390, pt 
0.0001 and pi  0.0675.
DISCUSSION
Cardiac remodeling and MMPs. The activation of
MMPs has been reported in the failing myocardium in
several experimental animal models. Dynamic expression
and activation of MMPs have been implicated in the
morphologic changes that occur after myocardial infarction
in either infarct-related or peri-infarct regions (8). In swine
with pacing-induced heart failure, the activities of MMP-1,
-2 and -3 increased, along with an increase in the LV
end-diastolic diameter (7). Thus, the increased MMPs
might be closely associated with the geometric remodeling
in diseased hearts. This hypothesis was further supported by
long-term pharmacologic interventions in rats (17,19). In
the present study, although the MMP activation occurred
during the transition to CHF around the age of 17 weeks in
DS rats, the collagen level did not show a decrease; rather,
it was increased by 13% (data not shown). That is, the
increased fibrosis could mask a small but significant decrease
in the structural collagen matrix that surrounds myocytes,
myofibrils and muscle bundles. Increased MMP activity
may induce this decrease in the structural collagen matrix
during the process of LV remodeling in the transition to
heart failure. This issue can be addressed by an evaluation of
the ultrastructural collagen matrix, but this is beyond the
scope of our current research.
Our data indicate that the net MMP-2 activation may be
the determining factor for LV enlargement and dysfunction.
Two structural mechanisms have been identified in the
pathogenesis of ventricular dilation in the failing heart. One
is the side-to-side slippage of myocytes, and the other is the
elongation of myocytes (20). Spinale et al. (4) reported that
MMP activity was increased and the fibrillar collagen weave
appeared reduced and disrupted in pigs with CHF caused by
pacing-induced supraventricular tachycardia. Tyagi et al.
(18) measured soluble collagen-derived peptide of type I
collagen in cardiac extracts obtained from patients with
Figure 1. Results of measurement of tissue inhibitor of matrix metalloproteinase (TIMP) activity in left ventricular extracts of Dahl salt-sensitive (DS) and
Dahl salt-resistant (DR) rats at the left ventricular hypertrophy (LVH) and congestive heart failure (CHF) stages. The TIMP activity was measured by
reverse zymography. The data are expressed as arbitrary units (values for 11-week-old DR rats were set at 1.0, and remaining values were adjusted
accordingly) and mean values  SEM (n  8 per group). *p  0.01; pa  0.0113; pt  0.0005; pi  0.0018. W  weeks.
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Figure 2. Results of measurement of tissue inhibitor of matrix metalloproteinase (TIMP) protein (A) and messenger ribonucleic acid (mRNA) (B) in left
ventricular extracts of Dahl salt-sensitive (DS) and Dahl salt-resistant (DR) rats at the left ventricular hypertrophy (LVH) and congestive heart failure
(CHF) stages. The TIMP-2 and -4 proteins and mRNA were measured by Western and Northern blot analyses, respectively. The TIMP mRNA level
was normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. The data are expressed as arbitrary units (values for 11-week-old
DR rats were set at 1.0, and remaining values were adjusted accordingly) and mean values  SEM. *p  0.01. †p  0.05. (A) pa  0.0207, pt  0.7292
and pi  0.0127 for TIMP-2 by Western blot; pa  0.0002, pt  0.0002 and pi  0.0021 for TIMP-4 by Western blot. (B) pa  0.0746, pt  0.0001
and pi  0.1669 for TIMP-2 mRNA by Northern blot; pa  0.0007, pt  0.0050 and pi  0.1804 for TIMP-4 mRNA by Northern blot. W  weeks.
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dilated cardiomyopathy. They demonstrated that the
collagen-derived peptide level, which indicates collagen
degradation, was increased in the myocardium with dilated
cardiomyopathy, as compared with normal hearts. Because
MMP activation directly leads to degradation or damage of
the fibrillar collagen network that connects myocytes, this
mechanism might lead to a reduction in the myocardial
contractile force, muscle fiber slippage and realignment,
with thinning of the myocardium, and eventual chamber
dilation.
Relationship between MMPs and TIMPs. The TIMPs
participate in the endogenous system, which provides post-
translational regulation of MMP activity in various tissues,
including the myocardium (21). In this study, TIMP-2 and
-4 were detected by reverse zymography and immunoblot-
ting of the LV myocardium. Both TIMP proteins were
upregulated in a manner parallel with MMPs. Active forms
of MMPs are inhibited by an interaction with the amino-
terminal domain of TIMPs, which form tight-binding, 1:1
complexes with active enzyme sites. In addition, TIMP-2
and -4 form specific complexes with latent MMP-2, pre-
sumably by an interaction between the carboxyl-terminal
domains of both the enzyme and inhibitor (22). In contrast,
recent studies have demonstrated that the MMP-2 activa-
tion process required the formation of the ternary activating
complex of MMP-2/TIMP-2/membrane type 1-MMP.
Thus, TIMP-2 promotes the activation of MMP-2 by
forming complexes with MMP-2 and membrane type
1-MMP. Mazzieri et al. (23) reported that surface-bound
pro–MMP-2 also can be activated by the cell surface-
associated urokinase-type plasminogen activator/plasmin
system. These lines of evidence suggest that the simple ratio
of TIMP-2 to MMP-2 can be misleading in terms of
measuring the absolute amount of proteolytic activity.
Therefore, we determined the absolute MMP-2 activity by
an antibody capture method.
Characteristics of cardiac TIMPs in heart failure. Al-
though each of the four known TIMPs is encoded by a
unique gene and has tissue-specific expression, it is known
that all four isoforms are expressed in the human heart.
Li et al. (24) reported that TIMP-1 and -3 were signifi-
cantly reduced in patients with end-stage heart failure,
whereas the TIMP-2 and -4 transcripts appeared un-
changed in the failing myocardium. In the present study, we
could not detect the activities of other TIMPs (TIMP-1
and -3) by reverse zymography in the LV myocardium of
experimental rats. This difference may result from several
causes, including the following explanation: in patients with
end-stage heart failure, the disease process is usually over a
period of years, during which a number of pharmacologic
interventions, including angiotensin-converting enzyme in-
hibitors, beta-adrenergic blockers or catecholamines, might
be continuously prescribed. In our animal model showing
the transition to heart failure, the controlled experimental
condition revealed that TIMP-1 and -3 activation does not
necessarily occur in this setting, and that TIMP activation
was not persistent, but rather timed with the stress event.
Actually, Chua et al. (25) reported that angiotensin II
induces upregulation of TIMP-1 in endothelial cells of the
rat heart. Thus, it is conceivable that factors such as
Figure 3. Gelatin zymography of commercially available matrix metallo-
proteinase (MMP)-2 and left ventricular (LV) extracts of rats. (A) Results
of measurement of MMP activity in LV extracts of Dahl salt-sensitive
(DS) and Dahl salt-resistant (DR) rats at the left ventricular hypertrophy
(LVH) and congestive heart failure (CHF) stages, and (B) representative
gelatin zymograms. (C) We calculated the ratio of the 68- to 72-kDa bands
on the zymogram. The data are expressed as arbitrary units (values for
11-week-old DR rats were set at 1.0, and remaining values were adjusted
accordingly) and mean values  SEM (n  8 per group). *p  0.01; †p 
0.05. (B) pa  0.061, pt  0.0001 and pi  0.0006. (C) pa  0.0134,
pt  0.0131 and pi  0.0103. W  weeks.
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interleukin-1-beta, tumor necrosis factor-alpha and trans-
forming growth factor-beta1, which have been strongly
associated with the transition to heart failure in this animal
model (26), might regulate TIMP expression (10).
Conclusions. Both TIMPs and MMPs remained inactive
during the process of hypertrophy, per se, but were activated
during the transition to CHF. At this time, the activation of
MMPs surpassed that of TIMPs, which might induce the
structural collagen matrix breakdown, resulting in the pro-
gression to LV enlargement.
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